<DOC>
	<DOCNO>NCT02139943</DOCNO>
	<brief_summary>The purpose study assess effect administration canagliflozin 100 mg 300 mg , compare placebo addition insulin therapy treatment Type 1 Diabetes Mellitus ( T1DM ) .</brief_summary>
	<brief_title>A Study Effects Canagliflozin Add-on Therapy Insulin Treatment Participants With Type 1 Diabetes Mellitus ( T1DM )</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know identity assign treatment ) , placebo-controlled ( inactive substance compare medication test whether medication real effect ) parallel-group , multicenter study canagliflozin addition insulin therapy participant type 1 diabetes mellitus inadequate glycemic control . Approximately 330 participant randomly assign 1:1:1 ratio either canagliflozin 100 mg , canagliflozin 300 mg , placebo group . About 90 participant ( 30 per treatment group ) select substudy purpose continuous glucose monitoring ( CGM ) assessment 7 day baseline 7 day end treatment . The total duration participation 22 week , participant need return investigational site approximately 9 visit . During study participant receive advice treatment hypoglycemia diabetic ketoacidosis ( DKA ) , well compliance diet exercise .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Must type 1 diabetes mellitus ( T1DM ) least 1 year Must inadequate glycemic control ( define glycosylated hemoglobin level &gt; = 7.0 % &lt; = 9.0 % ) basal plus bolus insulin screen Must body mass index 21 35 kg/m2 inclusive Must total daily dose insulin &gt; = 0.6 IU/kg screening Must stable insulin regimen least 8 week prior screen History T2DM , pancreas Î²cell transplantation , diabetes secondary pancreatitis pancreatectomy Severe hypoglycemia ( defined event require assistance another person , result seizure loss consciousness ) within 6 month prior study start Diabetic ketoacidosis within 6 month prior study start History hereditary glucosegalactose malabsorption primary renal glycosuria An ongoing , inadequately control thyroid disorder</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Continuous Glucose Monitoring</keyword>
</DOC>